Adagene Forms Clinical Partnership with Incyte for Phase 1 MSS CRC Study of Muzastotug
ADAG has more than doubled off its 52-week low of $1.3.
Summary
Adagene Inc. has announced a clinical collaboration with Incyte to initiate a Phase 1 study evaluating Adagene's muzastotug (ADG126) in combination with Incyte's INCA33890 for patients with microsatellite stable colorectal cancer (MSS CRC). This partnership is significant for Adagene, a smaller biotech, as Incyte will sponsor and conduct the study, reducing Adagene's financial burden while validating its SAFEbody® technology and muzastotug as a potential backbone immunotherapy. The collaboration aims to explore novel combination approaches for MSS CRC, a disease notoriously resistant to current immunotherapies, and could provide crucial clinical insights into improving response rates and extending survival. This follows recent positive corporate updates and clinical data reported by Adagene, indicating continued progress in its pipeline. Investors will watch for initial data from this Phase 1 study, expected to begin in 2026.
At the time of this announcement, ADAG was trading at $4.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $184.8M. The 52-week trading range was $1.30 to $4.72. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.